GlassScriptPhysician profile
Alan K Cu Chiam
NPI 1912069022
$3,350.89
in general payments reported to CMS, 2019-2025
30 companies · $930 in 2025
The $930 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $189 · 2021: $611 · 2022: $568 · 2023: $358 · 2024: $502 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,027.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $332.57 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $222.48 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $214.72 | 2022-2025 | Zoryve |
| Abbott Laboratories | $173.94 | 2021-2024 | Mitraclip |
| Gilead Sciences, INC. | $149.51 | 2019-2025 | Biktarvy |
| Janssen Pharmaceuticals, INC | $96.22 | 2020-2021 | |
| Lilly USA, LLC | $95.22 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $91.67 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $91.62 | 2021-2022 | |
| Medtronic, INC. | $89.37 | 2025 | Interstim |
| Novo Nordisk INC | $67.88 | 2019-2022 | |
| Astellas Pharma US INC | $67.65 | 2021-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $64.65 | 2021-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $60.95 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.72 | 2020-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.86 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Baxter Healthcare | $43.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $40.94 | 2020-2021 | |
| Exact Sciences Corporation | $40.73 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $40.39 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $37.95 | 2021-2022 | |
| Lundbeck LLC | $32.93 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $25.88 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.30 | 2021 | |
| Sumitomo Pharma America, INC. | $18.58 | 2025 | Myfembree |
| Actelion Pharmaceuticals US, INC. | $18.39 | 2024 | Uptravi, Opsumit |
| Mannkind Corporation | $16.76 | 2022 | |
| Dexcom, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cu Chiam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.